Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin

Inclusion criteria

• Healthy
• Postmenopausal
• Body weight > 50 kg
• Body mass index (BMI) between 19 and 30
• The subject is willing and able to give a signed and dated written informed consent prior to admission to the study
• The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria

• Subjects with known morphea or sclerodermia
• Subjects with a history of myocardial infarction.
• Subjects with a history of renal/or hepatic disease unless the disease has been successfully treated and is no longer active; subjects with any evidence of renal/ or hepatic impairment on the screening physical and laboratory examination.
• Subjects with history of hypertension or systolic blood pressure
• Subjects with history of diabetes
• History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
• History of use of tobacco- or nicotine-containing products within 6 months of screening, or a positive urine cotinine indicative of smoking at screening.
• Positive urine drug screen including alcohol (or alcohol breath test) at screening.
• Positive for HIV, hepatitis B virus or hepatitis C virus.
• Donation of blood in excess of 500 mL within 56 days prior to dosing
• History of sensitivity or contraindications to any of the study medications (i.e., relacatib, paracetamol, ibuprofen or atorvastatin) or components thereof.
• Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
• Subjects whom are judged by the investigator to be at risk for acute angle closure glaucoma.